S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
NASDAQ:VTGN

Vistagen Therapeutics (VTGN) Stock Price, News & Analysis

$4.57
+0.22 (+5.06%)
(As of 03/27/2024 ET)
Today's Range
$4.31
$4.65
50-Day Range
$3.92
$5.42
52-Week Range
$1.62
$24.71
Volume
245,899 shs
Average Volume
246,339 shs
Market Capitalization
$123.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Vistagen Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
315.8% Upside
$19.00 Price Target
Short Interest
Healthy
5.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Vistagen Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.56) to ($2.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

Medical Sector

653rd out of 939 stocks

Pharmaceutical Preparations Industry

304th out of 435 stocks

VTGN stock logo

About Vistagen Therapeutics Stock (NASDAQ:VTGN)

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

VTGN Stock Price History

VTGN Stock News Headlines

30 Countries with the Lowest Depression Rates
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
VTGN Apr 2024 10.000 call
Vistagen to Present at Stifel 2024 Virtual CNS Days
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
3 Revolutionary Biotech Stocks Poised for 10X Surge
Vistagen Therapeutics Inc VTGN
Recap: Vistagen Therapeutics Q3 Earnings
VistaGen Therapeutics's Earnings: A Preview
See More Headlines
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/27/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
6/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTGN
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$30.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+315.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-59,250,000.00
Net Margins
-3,073.51%
Pretax Margin
-3,073.22%

Debt

Sales & Book Value

Annual Sales
$1.11 million
Book Value
$1.65 per share

Miscellaneous

Free Float
26,171,000
Market Cap
$123.48 million
Optionable
Optionable
Beta
0.78
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Shawn K. Singh J.D. (Age 61)
    CEO & Director
    Comp: $600k
  • Mr. Reid G. Adler Esq. (Age 69)
    J.D., Chief Corporate Development Officer & General Counsel
    Comp: $371.88k
  • Ms. Cynthia Lynn Anderson CPA (Age 55)
    Chief Financial Officer
  • Mr. Joshua Prince M.B.A. (Age 54)
    Chief Operating Officer
  • Mr. Mark Adrian McPartland (Age 58)
    Senior Vice President of Investor Relations
    Comp: $300k
  • Ms. Trisha Fitzmaurice
    Senior Vice President of Human Resources
  • Dr. Allen Easley Cato III
    M.D., Ph.D., Senior Vice President of Development Operations
  • Dr. Mark J. Ginski Ph.D. (Age 52)
    Senior VP and Head of Chemistry, Manufacturing & Controls
  • Mr. Mark Flather
    Senior Vice President of Corporate Strategy & Capital Markets
  • Dr. Erik Berglund M.D.
    Ph.D., Senior VP of Global Regulatory Affairs & Pharmacovigilance

VTGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Vistagen Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTGN shares.
View VTGN analyst ratings
or view top-rated stocks.

What is Vistagen Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 1-year price objectives for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they expect the company's share price to reach $19.00 in the next year. This suggests a possible upside of 315.8% from the stock's current price.
View analysts price targets for VTGN
or view top-rated stocks among Wall Street analysts.

How have VTGN shares performed in 2024?

Vistagen Therapeutics' stock was trading at $5.14 at the beginning of the year. Since then, VTGN shares have decreased by 11.1% and is now trading at $4.57.
View the best growth stocks for 2024 here
.

When is Vistagen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024.
View our VTGN earnings forecast
.

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) issued its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.09. The business earned $0.41 million during the quarter, compared to analyst estimates of $0.73 million. Vistagen Therapeutics had a negative net margin of 3,073.51% and a negative trailing twelve-month return on equity of 72.10%.

When did Vistagen Therapeutics' stock split?

Vistagen Therapeutics's stock reverse split on the morning of Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

Who are Vistagen Therapeutics' major shareholders?

Vistagen Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (7.40%), Great Point Partners LLC (6.88%), Vanguard Group Inc. (6.79%), Vanguard Group Inc. (6.79%), Nantahala Capital Management LLC (6.72%) and Sphera Funds Management LTD. (2.99%). Insiders that own company stock include Commodore Capital Lp, H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par.
View institutional ownership trends
.

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners